Author

N. Roca

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 1 Organism:rat· 1

Frequent Co-Authors

B. Clotet· 3 shared J. Blanco· 3 shared J. Rodon· 3 shared J. Segales· 3 shared J. Vergara-Alert· 3 shared M. Perez· 3 shared A. Valencia· 2 shared B. Trinite· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

B. Clotet

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant.

J. Carrillo, C. Avila-Nieto, J. Vergara-Alert, P. Amengual-Rigo, E. Ainsua-Enrich, M. Brustolin, M. L. Rodriguez de la Concepcion, N. Pedreno-Lopez, J. Rodon, V. Urrea, E. Pradenas, S. Marfil, E. Ballana, E. Riveira-Munoz, M. Perez, , J. Segales

This paper identifies mutations that improve the production and efficacy of SARS-CoV-2 Spike proteins, protecting animal models from the Beta variant.

bioRxiv · Jul 7, 2023Immunology

Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2

A. Barreiro, A. Prenafeta, G. Bech-Sabat, M. Roca, E. Perozo, R. March, L. Gonzalez-Gonzalez, L. Madrenas, J. Corominas, A. Fernandez, A. Moros, M. Molas, T. Pentinat-Pelegrin, C. Panosa, A. Moreno, , Barr

This paper evaluates a recombinant RBD fusion heterodimer vaccine in mice, showing 100% efficacy against SARS-CoV-2 variants and neutralizing antibodies.

bioRxiv · Nov 22, 2021Immunology

Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in hamsters

M. Brustolin, J. Rodon, M. L. Rodriguez de la Concepcion, C. Avila-Nieto, G. Cantero, M. Perez, T. Nigeer, M. Noguera-Julian, V. Guallar, A. Valencia, N. Roca, N. Izquierdo-Useros, J. Blanco, B. Clotet, A. Bensaid, , J. Segales

This study shows that hamsters infected with SARS-CoV-2 are not fully protected against reinfection with both original and variant isolates, but experience reduced lung disease severity upon re-exposure.

bioRxiv · Jan 7, 2021 · PreprintPathology